NEW YORK (GenomeWeb News) – Nanogen and Fisher Scientific International today said they will share each other's technology and patent rights in order to develop, manufacture, and market new molecular diagnostic products.
As part of the deal, which complements Fisher's equity investment in Nanogen in March, Fisher “may provide” Nanogen up to $10 million during 2007 and 2008 to research and develop infectious disease and molecular diagnostic tests “that will be mutually agreed upon.”
Additionally, Nanogen and Fisher’s Athena Diagnostics subsidiary plan to manufacture and market products based on Athena's biomarkers for research and for in vitro diagnostic use.
Athena has markers in neurology and endocrinology that it has incorporated into its testing service, several of which could be incorporated into assays for use on Nanogen's NanoChip400 microarray platform, Fisher and Nanogen said.
“Likewise,” Nanogen has access to a “wide range of markers” that could be used to create tests for the Athena Diagnostics testing service.
Additional details were not disclosed.